DOES PRACTICE MAKE PERFECT?
DO THE NUMBER OF NICE AND SMC SUBMISSIONS A COMPANY MAKES CORRELATE WITH SUCCESS RATES?

INTRODUCTION
• NICE and the SMC are health technology bodies that issue guidance on whether health technologies should be adopted by their respective health systems (NICE: England and Wales, SMC: Scotland) based upon their clinical and cost effectiveness, with the Incremental Cost Effectiveness Ratio as a key criteria for both.
• This research aims to compare how success rate varies by manufacturer.

RESULTS

NICE recommendations by manufacturer
• 216 NICE STA appraisals were identified by 52 manufacturers, 46% were “approved” – defined as “recommended” or “optimised”.
• The three manufacturers who made the most frequent NICE submissions were:
  • Roche (30, 57% approved),
  • Novartis (20, 45% approved)
  • Janssen-Cilag (14, 71% approved).
• The most successful (with ≥10 appraisals) were:
  • Boehringer Ingelheim (10, 100% approved)
  • Merck Sharp and Dohme (10, 80% approved)
  • Novartis (92, 57% approved),
• The three manufacturers who made the most frequent SMC submissions were:
  • Novartis (92, 57% approved),
  • Roche (67, 66% approved), and
  • Merck Sharp and Dohme (62, 79% approved).
• The most successful (with ≥10 appraisals) were:
  • Merck Sharp and Dohme
  • Roche (67, 66% approved), and
  • Novartis (92, 57% approved),
  • Celgene (6, 50% approved).

SMC recommendations by manufacturer
• 1255 SMC appraisals were identified by 165 different manufacturers, 61% were “approved” – defined as “accepted” or “restricted”.
• The three manufacturers who made the most frequent SMC submissions were:
  • Novartis (92, 57% approved),
  • Roche (67, 66% approved), and
  • Merck Sharp and Dohme (62, 79% approved).
• The most successful (with ≥10 appraisals) were:
  • Astellas (13, 92% approved)
  • Boehringer Ingelheim (31, 90% approved)
• The least successful (with ≥10 appraisals) were:
  • Amgen (18, 17% approved)
  • Menarini (11, 18% approved).
• There was no significant correlation between the number of SMC and NICE appraisals and their success rates.

CONCLUSIONS
• There is a wide range of NICE and SMC acceptance rates between companies, but success rates do not correlate with the number of submissions a company makes, suggesting that this difference may be reflected by the distinct portfolios of drugs of different companies and/or their pricing policies.